Status:
WITHDRAWN
Oral Pyrophosphate Absorption in PXE Disease
Lead Sponsor:
Tampere University Hospital
Collaborating Sponsors:
UMC Utrecht
Hungarian Academy of Sciences
Conditions:
Pseudoxanthoma Elasticum
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves ...
Detailed Description
Phase II oral capsulized disodium-PPi (Na2H2PPi) powder absorption study in subjects with PXE (n=8-12) will be done in the ward of Internal Medicine of Tampere University Hospital and University Medic...
Eligibility Criteria
Inclusion
- Adults (\>18 yrs)
- clinically and genetically proven PXE
- Body mass index (BMI) 18,5-34,9 kg/m2
Exclusion
- Special groups according to researchers' decision.
- Pregnancy
- No effective contraception in females in child-bearing age.
Key Trial Info
Start Date :
December 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04441671
Start Date
December 8 2020
End Date
April 1 2021
Last Update
April 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.